<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474367</url>
  </required_header>
  <id_info>
    <org_study_id>97/2017</org_study_id>
    <nct_id>NCT03474367</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness of Urgent-start Therapies Hemodialysis and Peritoneal Dialysis</brief_title>
  <official_title>Cost-effectiveness of Urgent-start Therapies Hemodialysis and Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite evidence of worse outcomes, initiation of renal replacement therapy by unplanned
      modalities in chronic kidney disease (CKD) patients is the reality in the practice for both
      hemodialysis and peritoneal dialysis. Unplanned therapy peritoneal dialysis (PD) is the
      initiation of the modality in less than 48 hours after implantation of the peritoneal
      catheter, without family training or adequacy of the home. Unplanned hemodialysis (HD) is the
      initiation of the method without a functional arteriovenous fistula, i.e., with a central
      venous catheter (nontunneled or tunneled).

      Growing evidence shows unplanned PD (or urgent start PD) as a viable and safe alternative to
      unplanned HD, with the similar rates of infection and survival.

      On planned scenario, solid studies demonstrate that PD has a better cost-effectiveness when
      compared to HD, however the literature lacks in this kind of analysis in unplanned methods.

      Briefly, the workgroup will follow patients that would anyway start a Renal Replacement
      Therapy by an unplanned method and register Government payment for the therapy, including the
      therapy direct costs and the costs with events (internation, infection), access for dialysis,
      laboratory and CKD specific medications to performed a cost-effectiveness analysis in both
      groups (Unplanned Hemodialysis and Unplanned Peritoneal Dialysis).

      The workgroup is responsible for the placement of the catheters (PD and HD) using the
      Seldinger Technique.

      The study is unicentric, the therapy is continuous and necessary for the maintenance of life;
      therefore, no great difficult in the follow up is expected. A database with up-to-date
      information of patients will be functional during the study.

      A Markov model will be developed to assess the relative cost-effectiveness of different
      dialysis modality distribution scenarios versus current practice. The model considers a
      hypothetical adult incident patient cohort with end-stage renal disease (ESRD) requiring
      dialysis and adopts payer perspective. Markov models have been used to model dialysis
      treatment in previous economic analyses and are widely accepted to be suitable for modelling
      chronic condition

      Statistical analysis plan:

      From the study protocol, the data will be entered in a spreadsheet and verified typographical
      errors and their analysis will be performed using the statistical program Statistical
      Analysis System (SAS) for Windows (version 9.2: SAS Institute, Cary, North Carolina, USA,
      2012).

      Considering an alpha error of 0.05 and a beta error of 0.2, power of statistic test of 0.8
      and cost difference detection between groups of 15%, the calculated sample size for each
      group is 94 patients.

      Initially descriptive analysis will be done for all patients treated in the period,
      calculated measures of central tendency and dispersion for continuous variables and
      frequencies for categorical variables.

      For the analysis of repeated measures, asymmetric distribution (gamma) under the Generalized
      Linear Model (GENMOD) procedure will be used.

      Chi Square will be used to compare categorical variable between the two groups. T test or
      Mann-Whitney will be used to compare parametric continue variables.

      By the utilization of Kaplan Meyer and log rank, survival curves of the two groups will be
      presented at the end of the study. A p-value of 5% or lower will be considered to be
      statistically significant
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 12, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost effectiveness analysis of unplanned PD and HD at the General Hospital of the School of Medicine of Botucatu (HC-FMB)</measure>
    <time_frame>6 months</time_frame>
    <description>Cost effectiveness analysis of unplanned PD and HD with the data collected at our center</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness analysis of unplanned PD and HD in national and international scenario</measure>
    <time_frame>6 months</time_frame>
    <description>Transpose the cost-effectiveness analysis to a national and international scenario, using a Markov model</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Cost-effectiveness Analysis</condition>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Unplanned Peritoneal Dialysis</arm_group_label>
    <description>CKD patients stage 5 (eGFR &lt; 15 ml/min/1,73m²) or stages 4 with abrupt worsening requiring dialysis treatment immediately followed or not by nephrologists prior to renal replacement therapy (RRT) indication that agree to initiate PD in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home and don't have any absolute contraindications. Absolute contraindication to the PD method are: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2&gt; 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unplanned Hemodialysis</arm_group_label>
    <description>CKD patients stage 5 (eGFR &lt; 15 ml/min/1,73m²) or stages 4 with abrupt worsening requiring dialysis treatment immediately followed or not by nephrologists prior to RRT indication that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Incident dialysis patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatorial Chronic Kidney Disease patients stage 5 (eGFR &lt; 15 ml/min) or stages 4
             with abrupt worsening requiring dialysis treatment immediately followed or not by
             nephrologists prior to Renal Replacement Therapy indication.

        Exclusion Criteria:

          -  Transitions between HD and PD

          -  Patients with functional arteriovenous fistula entering hemodialysis

          -  Patients with functional PD access implanted ate least 48h before the first use

          -  Patient or family trained in PD and/or with the right adequacy of the home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Minetto Brabo, Mastering Student</last_name>
    <phone>+55 15 9 9753-6608</phone>
    <email>alexandrembrabo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <zip>18606-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre M Brabo, Physisian</last_name>
      <phone>+5515997536608</phone>
      <email>alexandrembrabo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Ponce, Doctor</last_name>
      <phone>+551438116008</phone>
      <email>dponce@fmb.unesp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://kidney.org/kidneydisease/global-facts-about-kidney-disease</url>
    <description>National Kidney Foundation. 2016</description>
  </link>
  <link>
    <url>https://www.usrds.org/2015/view/</url>
    <description>U.S. Renal Data System. USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: USRDS; 2015</description>
  </link>
  <link>
    <url>http://www.nephrology.dk</url>
    <description>Danish Nephrology Registry, Annual Report 2011</description>
  </link>
  <link>
    <url>http://www.sbn.org.br</url>
    <description>Census of the Brazillian Society of Nephrology 2014</description>
  </link>
  <reference>
    <citation>Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2012 May;81(10):1044-5. doi: 10.1038/ki.2012.39.</citation>
    <PMID>22543907</PMID>
  </reference>
  <reference>
    <citation>Eggers PW. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens. 2011 May;20(3):241-5. doi: 10.1097/MNH.0b013e3283454319.</citation>
    <PMID>21422925</PMID>
  </reference>
  <reference>
    <citation>Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evaluation of dialysis therapies. Nat Rev Nephrol. 2014 Nov;10(11):644-52. doi: 10.1038/nrneph.2014.145. Epub 2014 Aug 26. Review.</citation>
    <PMID>25157840</PMID>
  </reference>
  <reference>
    <citation>Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant. 2011 Sep;26(9):2988-95. doi: 10.1093/ndt/gfq780. Epub 2011 Feb 10.</citation>
    <PMID>21310740</PMID>
  </reference>
  <reference>
    <citation>Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology (Carlton). 2009 Feb;14(1):123-32. doi: 10.1111/j.1440-1797.2008.01073.x.</citation>
    <PMID>19207859</PMID>
  </reference>
  <reference>
    <citation>Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT; NECOSAD Study Group. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 2003 Dec;64(6):2222-8.</citation>
    <PMID>14633146</PMID>
  </reference>
  <reference>
    <citation>Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl. 2006 Nov;(103):S3-11. Review.</citation>
    <PMID>17080109</PMID>
  </reference>
  <reference>
    <citation>Perl J, Wald R, McFarlane P, Bargman JM, Vonesh E, Na Y, Jassal SV, Moist L. Hemodialysis vascular access modifies the association between dialysis modality and survival. J Am Soc Nephrol. 2011 Jun;22(6):1113-21. doi: 10.1681/ASN.2010111155. Epub 2011 Apr 21.</citation>
    <PMID>21511830</PMID>
  </reference>
  <reference>
    <citation>Heaf JG, Løkkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant. 2002 Jan;17(1):112-7.</citation>
    <PMID>11773473</PMID>
  </reference>
  <reference>
    <citation>Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol. 2003 Nov;14(11):2851-60.</citation>
    <PMID>14569095</PMID>
  </reference>
  <reference>
    <citation>Dias DB, Banin V, Mendes ML, Barretti P, Ponce D. Peritoneal dialysis can be an option for unplanned chronic dialysis: initial results from a developing country. Int Urol Nephrol. 2016 Jun;48(6):901-6. doi: 10.1007/s11255-016-1243-x. Epub 2016 Feb 20.</citation>
    <PMID>26897038</PMID>
  </reference>
  <reference>
    <citation>Silva TN, de Marchi D, Mendes ML, Barretti P, Ponce D. Approach to prophylactic measures for central venous catheter-related infections in hemodialysis: a critical review. Hemodial Int. 2014 Jan;18(1):15-23. doi: 10.1111/hdi.12071. Epub 2013 Aug 14. Review.</citation>
    <PMID>23944971</PMID>
  </reference>
  <reference>
    <citation>Mendes ML, Castro JH, Silva TN, Barretti P, Ponce D. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients. Artif Organs. 2014 May;38(5):399-403. doi: 10.1111/aor.12186. Epub 2013 Oct 3.</citation>
    <PMID>24117542</PMID>
  </reference>
  <reference>
    <citation>Koch M, Kohnle M, Trapp R, Haastert B, Rump LC, Aker S. Comparable outcome of acute unplanned peritoneal dialysis and haemodialysis. Nephrol Dial Transplant. 2012 Jan;27(1):375-80. doi: 10.1093/ndt/gfr262. Epub 2011 May 28.</citation>
    <PMID>21622993</PMID>
  </reference>
  <reference>
    <citation>Lobbedez T, Lecouf A, Ficheux M, Henri P, Hurault de Ligny B, Ryckelynck JP. Is rapid initiation of peritoneal dialysis feasible in unplanned dialysis patients? A single-centre experience. Nephrol Dial Transplant. 2008 Oct;23(10):3290-4. doi: 10.1093/ndt/gfn213. Epub 2008 Apr 19.</citation>
    <PMID>18424817</PMID>
  </reference>
  <reference>
    <citation>Alkatheeri AM, Blake PG, Gray D, Jain AK. Success of Urgent-Start Peritoneal Dialysis in a Large Canadian Renal Program. Perit Dial Int. 2016 Mar-Apr;36(2):171-6. doi: 10.3747/pdi.2014.00148. Epub 2015 Sep 15.</citation>
    <PMID>26374834</PMID>
  </reference>
  <reference>
    <citation>Povlsen JV. Unplanned start on assisted peritoneal dialysis. Contrib Nephrol. 2009;163:261-3. doi: 10.1159/000223808. Epub 2009 Jun 3.</citation>
    <PMID>19494623</PMID>
  </reference>
  <reference>
    <citation>Chang YT, Hwang JS, Hung SY, Tsai MS, Wu JL, Sung JM, Wang JD. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score. Sci Rep. 2016 Jul 27;6:30266. doi: 10.1038/srep30266.</citation>
    <PMID>27461186</PMID>
  </reference>
  <reference>
    <citation>Atapour A, Eshaghian A, Taheri D, Dolatkhah S. Hemodialysis versus peritoneal dialysis, which is cost-effective? Saudi J Kidney Dis Transpl. 2015 Sep;26(5):962-5. doi: 10.4103/1319-2442.164578.</citation>
    <PMID>26354569</PMID>
  </reference>
  <reference>
    <citation>Liu FX, Ghaffari A, Dhatt H, Kumar V, Balsera C, Wallace E, Khairullah Q, Lesher B, Gao X, Henderson H, LaFleur P, Delgado EM, Alvarez MM, Hartley J, McClernon M, Walton S, Guest S. Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United States. Medicine (Baltimore). 2014 Dec;93(28):e293. doi: 10.1097/MD.0000000000000293.</citation>
    <PMID>25526471</PMID>
  </reference>
  <reference>
    <citation>Passadakis PS, Oreopoulos DG. Peritoneal dialysis in patients with acute renal failure. Adv Perit Dial. 2007;23:7-16. Review.</citation>
    <PMID>17886595</PMID>
  </reference>
  <reference>
    <citation>Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, Daly C, Stearns SC. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess. 2003;7(2):1-174. Review.</citation>
    <PMID>12773260</PMID>
  </reference>
  <reference>
    <citation>Kirby L, Vale L. Dialysis for end-stage renal disease. Determining a cost-effective approach. Int J Technol Assess Health Care. 2001 Spring;17(2):181-9. Review.</citation>
    <PMID>11446130</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Alexandre Minetto Brabo</investigator_full_name>
    <investigator_title>Mastering Student</investigator_title>
  </responsible_party>
  <keyword>Unplanned Peritoneal Dialysis</keyword>
  <keyword>Unplanned Hemodialysis</keyword>
  <keyword>Cost-Benefit Analysis</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

